基于天然高分子基元的阻隔层对磁性载药聚乳酸微球的控释作用

利用层层组装技术构建了基于天然高分子壳聚糖和海藻酸钠的阻隔层, 并研究了该阻隔层对磁性载药聚乳酸微球的药物释放作用. 实验结果表明, 阻隔层能够有效抑制模型药物的突释, 具有延缓药物释放的效果. 具有阻隔层的磁性载药体系具有药物释放平缓和生物相容性高等特点, 是理想的磁靶向载药体系.     

无毒催化剂催化合成外消旋聚乳酸及其在药物缓释微球中的应用

以D，L－乳酸单体为原料，使用人体营养添加剂如乳酸锌、乳酸钙，乙酸锌、硫酸锌、牛磺酸等作为无毒催化剂，通过熔融聚合直接合成低分子量的生物降解材料外消旋聚乳酸（PDLLA），粘均分子量接近4000，以PDLLA为载体，应用于制备抗菌药物环丙沙星聚乳酸微球，用DSC和SEM表征其成球性能，载药微球体外缓释半衰期为31．9h,53.2h后累积释药百分率约为84．0％，具有明显的缓释作用。     

生物降解聚酯包埋利福平缓释微球的制备及释放行为

以生物可降解乙交酯和丙交酯的无规共聚物(PLGA)为载体,将抗结核病药利福平溶解于PLGA的有机溶液中,采用通常乳化-溶剂挥发方法制备了药物缓释微球.研究了影响微球制备的工艺条件.用电子显微镜观察了微球及降解后的表面形态,测定了微球粒径及载药量,评价了载药微球的体外释放行为.结果表明,以质量分数为1%的明胶为稳定剂,制备的微球形态完整,粒径范围为10～30μm,微球中利福平的平均质量分数为24.3%.体外释药时间可以通过高分子的降解速率来调控,本实验的释药时间可以在42～84d之间调控,药物缓释达到了理想的零级动力学释放.因此,利福平PLGA微球具有显著的长效、恒量药物缓释作用.     

交联聚乳酸中空微球的制备与表征

由于聚乳酸具有良好生物相容性与降解性,故可用作控释给药系统的载体材料．有关聚乳酸及其共聚物微球药物载体、释放行为及微球表面引入基团使之功能化的方法研究已有报道．以其它生物大分子材料作为囊壁材料的缓释微胶囊也有报道,但以聚乳酸制备中空微囊型的药物释放载体却鲜有研究．通过控制分子量、微囊大小、囊壁厚度等参数,     

聚乳酸纳米粒的改性研究进展

聚乳酸纳米粒具有控制药物释放速度以达到长效缓释、增加药物靶向性、降低毒副作用以及提高疗效等优点,在药物传输中有着广阔的研究和应用前景。但由于聚乳酸的疏水性和分子链基团的单一性,它在靶向制剂和长效制剂的应用方面受到很大制约。本文对可生物降解材料聚乳酸作为载药纳米粒的改性研究状况进行了综述,针对目前制约聚乳酸纳米粒临床应用存在的问题,介绍了亲水性修饰、靶向修饰的最新研究进展。     

Research Progress on Modification of Poly（L-iactide） Nanoparticles

聚乳酸纳米粒具有控制药物释放速度以达到长效缓释、增加药物靶向性、降低毒副作用以及提高疗效等优点,在药物传输中有着广阔的研究和应用前景。但由于聚乳酸的疏水性和分子链基团的单一性,它在靶向制剂和长效制剂的应用方面受到很大制约。本文对可生物降解材料聚乳酸作为载药纳米粒的改性研究状况进行了综述,针对目前制约聚乳酸纳米粒临床应用存在的问题,介绍了亲水性修饰、靶向修饰的最新研究进展。     

左旋甲基多巴分子印迹纳米给药系统的合成、表征及药物缓释研究

采用沉淀聚合法合成了左旋甲基多巴(L-Methyldopa, LMD)分子印迹聚合物微球(MIPMs), 并对其合成条件进行了详细研究. 结果表明, 聚合温度和引发剂的用量对微球的大小和形态有较大的影响, 微球的粒径随聚合温度的降低而增大, 随偶氮二异丁睛(AIBN)量的增大而增大. 而模板分子似乎对微球粒径的影响不是很明显. 通过扫描电镜、静态吸附试验(BET)和斯卡查德分析(Scatchard analysis)、红外光谱分析和模拟人体胃液扩散实验等对微球的外貌形态、吸附性能、分子印迹效果和药物缓释效果进行了表征. BET吸附实验和Scatchard 分析结果表明, 分子印迹聚合微球(MIPMs)的最大静态吸附量是非印迹聚合物微球(NIPMs)的3倍. 药物扩散实验表明, LMD在非印迹微球(NIPMs)上的释药率几乎与时间呈直线关系, 说明其释药过程完全受扩散控制; 而LMD在MIPMs上的释药率则呈曲线上升趋势, 说明其释药过程除了受扩散控制外, 还受到药物模板分子与MIPMs之间的印迹效应的协同作用的控制, 从而达到了缓释药物分子的目的. 实验结果表明, 在模拟胃液中, MIPMs释放药物的持续时间(10 h)是NIPMs持续时间(5 h)的2倍, 表明分子印迹微微球确实具有缓释药物的效果. 因此, MIPMs有望进一步应用于LMD药物缓释系统的研究.     

左旋甲基多巴分子印迹微球给药系统的合成、表征及药物缓释研究

采用沉淀聚合法合成了左旋甲基多巴(L-Methyldopa,LMD)分子印迹聚合物微球(MIPMs),并对其合成条件进行了详细研究.结果表明,聚合温度和引发剂的用量对微球的大小和形态有较大的影响,微球的粒径随聚合温度的降低而增大,随偶氮二异丁睛(AIBN)量的增大而增大.而模板分子似乎对微球粒径的影响不是很明显.通过扫描电镜、静态吸附试验(BET)和斯卡查德分析(Scatchardanalysis)、红外光谱分析和模拟人体胃液扩散实验等对微球的外貌形态、吸附性能、分子印迹效果和药物缓释效果进行了表征.BET吸附实验和Scatchard分析结果表明,分子印迹聚合微球(MIPMs)的最大静态吸附量是非印迹聚合物微球(NIPMs)的3倍.药物扩散实验表明,LMD在非印迹微球(NIPMs)上的释药率几乎与时间呈直线关系,说明其释药过程完全受扩散控制;而LMD在MIPMs上的释药率则呈曲线上升趋势,说明其释药过程除了受扩散控制外,还受到药物模板分子与MIPMs之间的印迹效应的协同作用的控制,从而达到了缓释药物分子的目的.实验结果表明,在模拟胃液中,MIPMs释放药物的持续时间(10h)是NIPMs持续时间(5h)的2倍,表明分子印迹微球确实具有缓释药物的效果.因此,MIPMs有望进一步应用于LMD药物缓释系统的研究.     

啶虫脒/二氧化硅复合微球的原位制备与缓释性能

利用正硅酸乙酯(TEOS)的原位水解缩合反应制备了啶虫脒/二氧化硅复合微球。采用FTIR、XRD、TG、SEM、DSC和粒度分析仪对复合微球的结构进行了表征,并探究了复合微球的释药行为。结果表明,所合成的复合微球是非晶态的,啶虫脒是以非晶相存在于复合微球中。复合微球呈现规则的球形形貌,微球粒径约为500-800 nm。微球具有良好的缓释性能,其释药行为可用Higuchi方程来描述,药物释放是扩散控制释放。     

天然高分子药物微球载体材料的研究进展

综述了国内外在天然高分子药物微球载体材料研究及应用中的进展状况,主要从天然高分子药物微球载体材料的分类、微球的制备方法及特点、载药微球的给药途径和应用等进行概括,并对目前所存在的问题进行了描述。     

The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method

Biodegradable polymeric microspheres are ideal vehicles for controlled delivery applications of drugs, peptides and proteins. Amongst them, poly(lactic-co-glycolic acid) (PLGA) has generated enormous interest due to their favorable properties and also has been approved by FDA for drug delivery. Insulin-loaded PLGA microparticles were prepared by our developed single phase oil in oil (o/o) emulsion solvent evaporation technique. Insulin, a model protein, was successfully loaded into microparticles by changing experimental variables such as polymer molecular weight, polymer concentration, surfactant concentration and stirring speed in order to optimize process variables on drug encapsulation efficiency, release rates, size and size distribution. A 2⁴ full factorial design was employed to evaluate systematically the combined effect of variables on responses. Scanning electron microscope (SEM) confirmed spherical shapes, smooth surface morphology and microsphere structure without aggregation. FTIR and DSC results showed drug–polymer interaction. The encapsulation efficiency of insulin was mainly influenced by surfactant concentration. Moreover, polymer concentration and polymer molecular weight affected burst release of drug and size characteristics of microspheres, respectively. It was concluded that using PLGA with higher molecular weight, high surfactant and polymer concentrations led to a more appropriate encapsulation efficiency of insulin with low burst effect and desirable release pattern.     

A detailed view of PLGA-mPEG microsphere formation by double emulsion solvent evaporation method

PLGA, m PEG diblock copolymer was synthesized by bulk ring-opening polymerization method. The double emulsion solvent evaporation method was used to prepare bovine serum albumin(BSA)-loaded microspheres. Optical microscopy was used to observe the whole microsphere fabrication process. It is confirmed that the proportion of inner aqueous phase is one of the most critical factors that determines the morphology of microspheres. Double emulsion droplets which have appropriate amount of inner aqueous phase can form closed and dense microspheres, while, too much inner aqueous phase will cause a collapse of the double emulsion droplets, resulting in a loss of drug. The proportion of inner aqueous phase was varied to prepare microspheres of different morphology. The results show that with increasing the amount of inner aqueous phase, a higher percent of broken microspheres and lower encapsulation efficiency appeared, and also, a more severe initial burst release and faster release rate.     

Release characteristics of cisplatin chitosan microspheres and effect of containing chitin

To increase cisplatin (CDDP) content, to suppress burst effect during the initial phase of drug release, and to improve the capacity of the system for sustained release, we prepared various types of CDDP chitosan microspheres incorporating chitin and investigated the content of CDDP and its in vitro release kinetics from these microspheres. The results of this study showed that the CDDP content increased with increasing chitosan concentration and that the incorporation of chitin in the carrier matrix produced a more pronounced increase in drug content. The addition of chitin also led to inhibition of the initial burst effect. The rate of CDDP release reduced with increasing concentration of chitosan: that is, the 50% CDDP release time was about 0.5 h with the microspheres prepared with 1.0% of chitosan and about 4.5 h with those prepared with 5.0% of chitosan, indicating about nine-fold prolongation. The addition of chitin further resulted in retardation of the rate of CDDP release. Meanwhile, our chitosan microspheres were shown to undergo enzymatic degradation by lysozymes.     

Thermal characteristics of poly (DL-lactic acid) microspheres containing neurotensin analogue.

The thermal characteristics of poly (DL-lactic acid) (DL-PLA) microspheres containing a hexapeptide (NA: H(CH3)-Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt) with neurotensin activity were investigated. PLA microspheres with a drug content of 1.5-11.0% were prepared by a novel o/w (oil-in-water) solvent evaporation method. Both DL-PLA and NA were amorphous in form, and an increase in heat capacity at glass transition temperature (Tg) of the polymer was observed in DL-PLA microspheres containing NA. The Tg of DL-PLA (PLA2000 bulk) was 307.8 K, while Tg of microspheres containing NA (content 6.0%) shifted to 321.2 K. The Tg of PLA2000 microspheres was found to increase with an increase in the content of NA, and its increasing tendency reached a plateau at an NA content of greater than 6%. The apparent activation energy of glass transition of PLA2000 bulk and the microspheres was calculated to be 86.3 and 99.3 kcal/mol, respectively. As a result of the release test after storage at 4 degrees C and 40 degrees C for 1 month, nearly the same release profiles of NA from PLA2000 microspheres were found. The release rate of NA after the initial release became slow after storage at 45 degrees C for 1 month. This may be attributed mainly to a decrease in surface area caused by the formation of agglomerates of PLA2000 microspheres under conditions near Tg.     

PLA/PEG/PLA三嵌段共聚物载药纳米胶囊的制备及表征

用于药物控释体系的微胶束具有实心微球结构,药物分子主要吸附于微球表面,极易脱落,在释药初期有明显的突释效应;而微胶囊的药物主要集中于囊心部分,药物通过扩散作用以及高分子膜的降解而逐渐释放到环境中,因而更有利于药物分子平稳、缓慢地释放．对于自然界中能够自发形成微胶囊的小分子材料,其分子中往往具有一个较小的亲水部分和一个相对较大的憎水部分,     

Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice

Huperzine A loaded poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres were prepared by an oil/water (o/w) solvent evaporation technique. With a decrease of the ratio of o/w from 1 : 100 to 1 : 50, the encapsulation efficiency was reduced about 4%. Increasing the PVA concentration from 0.5 to 2% reduced the percentage encapsulation efficiency of huperzine A from 60.7 to 47.4% and the particle size of microspheres from 84.2 to 26.2 microm. The addition of stearic acid improved the encapsulation efficiency, but also accelerated the in vitro release of hupezine A from microspheres. After i.m. administration of huperzine A loaded microspheres in mice, huperzine A was sustained released from the PLGA microspheres up to 12 d with a low initial burst. Passive avoidance test of mice showed that the microspheres formulation offered an improved therapeutic efficiency in the treatment of the impaired memory of the mice superior to injection gastric (i.g.) administration of huperzine A suspension at the same dose, whose therapeutic efficiency was similar as that of a 50% reduced dose of the microspheres formulation.     

Nanoencapsulation and characterization of Albizia chinensis isolated antioxidant quercitrin on PLA nanoparticles

The plant isolated antioxidant quercitrin has been encapsulated on poly-d,l-lactide (PLA) nanoparticles by solvent evaporation method to improve the solubility, permeability and stability of this molecule. The size of quercitrin-PLA nanoparticles is 250 ± 68 nm whereas that PLA nanoparticles is 195 ± 55 nm. The encapsulation efficiency of nanoencapsulated quercitrin evaluated by HPLC and antioxidant assay is 40%. The in vitro release kinetics of quercitrin under physiological condition reveals initial burst release followed by sustained release. Less fluorescence quenching is observed with equimolar concentration of PLA encapsulated quercitrin than free quercitrin. The presence of quercitrin specific peaks on FTIR of five times washed quercitrin loaded PLA nanoparticles provides an extra evidence for the encapsulation of quercitrin into PLA nanoparticles. These properties of quercitrin nanomedicine provide a new potential for the use of such less useful highly active antioxidant molecule towards the development of better therapeutic for intestinal anti-inflammatory effect and nutraceutical compounds.     

Enhanced gentamicin loading and release of PLGA and PLHMGA microspheres by varying the formulation parameters

The purpose of this study was to develop a suitable formulation for gentamicin sulfate (GS) that gives a sustained release of the drug. Therefore this drug was loaded into poly(D,L-lactide-co-glycolide) (PLGA) and poly(lactic-co-hydroxymethyl glycolic acid) (PLHMGA) microspheres. The effects of various formulation parameters (ethanol, surfactant, osmotic value of the external phase, polymer type and concentration) on particle characteristics (size, loading and release) were investigated. The GS loaded microspheres were prepared using a double emulsion evaporation technique. The results demonstrate that neither ethanol nor surfactants had beneficial effects on the drug loading efficiency (around 4-10%). However, an increase in buffer concentration (and thus osmotic pressure) of the external phase resulted in a substantial increase of GS-loading (from 10 to 28%). Further, an increase of concentration of PLGA in DCM from 10% to 15/20% caused a 4-time increase of the drug loading. The best formulation identified in this study had a loading efficiency of around 70% resulting in PLGA microspheres with a 6% (w/w) loading. The particles showed a burst release of the drug depending on their porosity, followed by a phase of 35 days where hardly any release occurred. The drug was then slowly released for around 25 days likely due to degradation of the microspheres. The drug loading efficiency of GS in PLHMGA was not significantly different from PLGA microspheres (64%). The release of GS from PLHMGA microspheres was faster than that of PLGA because the degradation rate of PLHMGA is more rapid than PLGA. This study shows that prolonged release of gentamicin can be obtained by loading this drug into microspheres made of biodegradable aliphatic polyesters.     

Encapsulation and release of biomolecules from Ca-P/PHBV nanocomposite microspheres and three-dimensional scaffolds fabricated by selective laser sintering

This study focused on the fabrication of calcium phosphate (Ca-P)/poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) nanocomposite scaffolds loaded with biomolecules using the selective laser sintering (SLS) technique and their evaluation. Ca-P/PHBV nanocomposite microspheres loaded with bovine serum albumin (BSA) as the model protein were fabricated using the double emulsion solvent evaporation method. The encapsulation efficiency of BSA in PHBV polymer microspheres and Ca-P/PHBV nanocomposite microspheres were 18.06 ± 0.86% and 24.51 ± 0.60%, respectively. The BSA loaded Ca-P/PHBV nanocomposite microspheres were successfully produced into three-dimensional porous scaffolds with good dimensional accuracy using the SLS technique. The nanocomposite microspheres served as protective carriers and maintained the bioactivity of BSA during SLS. The effects of SLS parameters such as laser power and scan spacing on the encapsulation efficiency of BSA in the scaffolds and in vitro BSA release were studied. An initial burst release was observed, which was followed by a slow release of BSA. After 28-day release, The PHBV matrix was slightly degraded after 28-day in vitro release study. It was shown that nanocomposite scaffolds with controlled architecture obtained via SLS could be incorporated with biomolecules, enhancing them with more functions for bone tissue engineering application or making them suitable for localized delivery of therapeutics.